Introduction
============

As a result of increased diagnostic accuracy and the wider application of mass surveys, the proportion of early gastric cancer (EGC) among resected gastric cancers has steadily increased, not only in Asia, but also in some Western countries \[[@R1]-[@R6]\]. Although the prognosis of EGC is excellent \[[@R7]-[@R9]\], EGC with lymph node metastasis (LNM) has a higher possibility of recurrence \[[@R10]-[@R12]\]. Because the presence of LNM is the most important prognostic factor for patients with EGC \[[@R3], [@R13]-[@R15]\], radical surgery with extended (D2) lymph node dissection (LND) has become the gold standard treatment for patients with EGC \[[@R16]-[@R19]\].

The prevalence of LNM in EGC ranges from 10% to 20% \[[@R20]-[@R24]\]. Therefore, at least 80% of patients will undergo unnecessary surgery with D2 lymphadenectomy \[[@R8], [@R25], [@R26]\]. Bonenkamp *et al*. \[[@R27]\] reported that patients with D2 lymph node resection have a higher operative mortality rate with more complications and a longer postoperative hospital stay. Recently, various minimally invasive procedures such as endoscopic mucosal resection and laparoscopic wedge resection without LND have been performed in selected EGC patients to improve the quality of life of long-term survivors \[[@R28]-[@R35]\]. For such procedures, the accurate prediction of LNM is crucial to determining the extent of LND.

Although it is extremely useful to know the involvement of lymph nodes before surgery, there is no simple and high sensitivity test to evaluate lymph node status preoperatively. Diagnostic imaging techniques including endoscopic ultrasound (EUS), computed tomography (CT), positron emission tomography (PET) and ultrasonography (US) are still unsatisfactory and do not provide enough evidence for an accurate prediction of metastasis in the regional lymph nodes draining gastric cancer because of their low sensitivity \[[@R36]-[@R41]\]. It is also difficult to diagnose such nodes during operation \[[@R42]\]. Because direct detection of LNM with high sensitivity is impossible yet, the indirect assessment of LNM in EGC is still based on the pathobiologic behaviors of the tumor \[[@R19], [@R43]\]. Accurate assessment of the pathobiologic behaviors of the tumor needs resected specimens. Biopsies are too superficial to provide the entire information of the tumor \[[@R13]\].

Conventional trans-abdominal US has been considered unsuitable for the detection of early staging lesions and LNM \[[@R44]\]. Oral contrast agent assisted US has been widely used to detect gastric cancer in China. In the present study, we sought to assess LNM of EGC preoperatively using double contrast-enhanced ultrasonography (DCUS), an oral ultrasonic contrast agent combined with an intravenous contrast agent.

Material and methods
====================

Eighty patients with EGC proven by pathology were examined with DCUS preoperatively between 2005 and 2009 after obtaining written informed consent. Of the 79 patients, 3 were excluded, one with advanced gastric cancer and the other 2 with the number of retrieved lymph nodes less than 15. The remaining 76 patients were enrolled in this study. The mean age of the patients was 58.3 years (range 35-83). The male to female ratio was 1.71 (48/28). Written informed consent was obtained from all patients. The ethics committee for our institution approved the study.

In this study, all patients underwent curative gastrectomy with D2 or more extended (D3) lymphadenectomy for primary early GC. Surgical resections were performed within 3 to 5 days after the DCUS examination. None of the patients in this study received nonsteroidal anti-inflammatory drugs, chemotherapy, radiotherapy, or immunotherapy before surgery. All of the subjects were divided into 2 groups according to their lymph nodes status postoperatively. Group N1 included 15 patients with LNM. Group N0 included 61 patients without LNM.

Double contrast-enhanced ultrasonography was performed after fasting for at least 6 h; Atropine sulfate injection (0.05 mg/kg) was administered via intramuscular injection half an hour before the examination to inhibit gastric peristalsis. An Acuson Sequoia 512 system (Siemens, Mountain View, CA), equipped with a 4V1 vector™ transducer (frequency: 1.0\~4.0 MHz) and contrast pulse sequencing (CPS) technology with auto-tracking contrast quantification (ACQ) software was used (Phillips and Gardner 2004).

The oral contrast agent Xinzhang® (Huqingyutang, HangZhou, China) was supplied as a microdot powder which was composed of a kind of soya derivative (48 g per package); it was reconstituted by adding 500 ml of boiling water and gently agitating the water by hand to form a homogeneous particulate suspension.

The distal esophagus of all patients was observed dynamically while the patients ingested the oral ultrasonic agent to expand the stomach and evacuate the air in stomach. Hence, the stomach lumen appeared as an iso-echoic homogenous acoustic window. Then the other parts of the stomach and the duodenal bulb were examined in turns with the patient in different body positions. When a suspected lesion was identified, it was measured routinely. If the lesion was smaller than 5 cm, it would be zoomed in for higher spatial resolution. Then after this procedure, a dynamic real-time contrast-enhanced sonography with CPS mode was performed using the following settings: insonating frequency 1.5 MHz and acoustic power, --15 to --21 dB. A low mechanical index (0.20) was selected to minimize microbubble disruption. Images of the ideal scanning plane were displayed in a real-time fashion by slightly changing the scanning plane to portray the whole area of the tumor.

Contrast-enhanced sonographic studies were performed after the administration of 2.4 ml of SonoVue (Bracco SpA, Milan, Italy) as a bolus via a 19-gauge peripheral intravenous cannula. The cannula was flushed with 10 ml saline. A timer on the sonography unit was activated at the beginning of injection, and the entire movie sequence (at least 5 min) was stored on magnetic optical disks for analysis. The contrast study could be repeated a second time if necessary.

The cine loops of the 69 lesions were retrospectively reviewed by 2 independent radiologists who are experts in sonography and microbubble contrast agents. Vascular enhancement of gastric carcinomas was visually classified into 3 patterns: hyper- enhancement, iso-enhancement, and hypo-enhancement. Hyper- enhancement was defined as a signal intensity over the whole tumor higher than the adjacent normal gastric wall during the whole arterial phase. Iso-enhancement was defined as a signal intensity over the whole tumor similar to the adjacent normal gastric wall during the whole arterial phase. Hypo-enhancement was defined as a signal intensity over the whole tumor lower than the adjacent normal gastric wall during the whole arterial phase. According to the pattern of enhancement, all cases were classified into the marked hyperenhancement group and the unmarked hyperenhancement group (including hypoenhancement and isoenhancement). The 2 reviewers were unaware of the definitive diagnosis and other imaging information at the time of the analysis. Double contrast-enhanced ultrasonography diagnoses were then compared with the final diagnosis based on the pathologic results.

Lymph nodes were meticulously dissected from the en bloc specimens, and the classification of the dissected lymph nodes was determined by surgeons who reviewed the excised specimens after surgery based on the Japanese Classification of Gastric Carcinoma. The primary tumor and retrieved lymph nodes were fixed in 10% formaldehyde solution, embedded in paraffin, incised into 4 mm sections, and mounted on poly-lysine-coated slides. These sections were stained by hematoxylin-and-eosin method to confirm their histological diagnosis and other microscopic characteristics. Experienced pathologists were employed to ensure a high quality of pathological diagnosis. The following clinicopathologic variables were evaluated: sex, age, location of tumor (lower third, middle third, upper third, or entire stomach), tumor diameter, histological type (differentiated: well differentiated, moderately differentiated, or papillary; undifferentiated: poorly differentiated, signet-ring cell, or mucinous), LNM, and depth of invasion (mucosa or submucosa).

Sensitivity, specificity and Youden's index were calculated for both oral contrast-enhanced ultrasonography and DCUS. Statistical evaluation was performed using the χ^2^ test or Fisher's exact test to differentiate the rates among the different groups. Student's *t*-test was used to analyze quantitative data. Kappa statistics was used to show the level of correlation in agreement between the 2 reviewers. Kappa values are categorized as follows \[[@R45]\]. Values between --1 and 0 indicate \"no agreement\"; between 0 and 0.20 indicate \"poor agreement\"; between 0.21 and 0.40 indicate \"slight agreement\"; between 0.41 and 0.60 indicate \"fair agreement\"; between 0.61 and 0.80 indicate \"good agreement\"; between 0.81 and 0.90 indicate \"very good agreement\"; and between 0.91 and 1.0 indicate \"excellent agreement\". For all analyses, a *p* value of less than 0.05 was considered statistically significant. All data were analyzed using SPSS13.0 statistical software (Chicago, IL, United States).

Results
=======

A total of 76 patients who had undergone gastrectomy with D2 or more extended (D3) lymphadenectomy for EGC at the 2^nd^ Affiliated Hospital of Wenzhou Medical College were studied. The number of retrieved lymph nodes in all patients was more than 15, ranging from 15 to 63 (median, 29.9). Lymph node metastasis was detected in 15 patients (19.7%), and the number of metastatic lymph nodes ranged from 1 to 36 (median 6.9).

In group N1, 13 patients (87%) had marked hyperenhancement compared with the adjacent normal gastric wall during the early arterial phase by using DCUS (Figure [1 C](#F1){ref-type="fig"}), and the other 2 patients (13%) had unmarked hyperenhancement. However, in group N0, 24 patients (39%) had marked early hyperenhancement compared to the adjacent normal gastric wall during the arterial phase using DCUS, and the other 37 patients had unmarked hyperenhancement (Figure [2 C](#F2){ref-type="fig"}). The sensitivity and specificity of marked hyperenhancement in predicting LNM in patients with early gastric cancer were 86.7% and 60.7%, respectively, and the Youden's index was 0.474 (Table [I](#T1){ref-type="table"}). The relationships between pathological characteristics of patients and the type of contrast enhancement are summarized in Table [II](#T2){ref-type="table"}.

Discussion
==========

Since LNM remains one of the most important predictors for survival, reduction in lymphadenectomy will probably result in a residue of metastatic lymph nodes \[[@R19]\]. Unnecessarily extended resection will induce a series of complications, which also result in a poor quality of life \[[@R10], [@R46], [@R47]\]. Thus, it is important to standardize the optimal extent of LND by investigating LNM of EGC preoperatively.

The low sensitivities of EUS, CT, US and PET are insufficient to allow decision making on the extent of lymphadenectomy \[[@R37]-[@R40]\]. Endoscopic ultrasound, MR and CT mainly depend on lymph node size as criteria to define malignancy \[[@R48]\]. Lymph nodes of less than 5 mm in diameter cannot be accurately detected by available imaging techniques \[[@R49]-[@R51]\]. In one study, 55% of the metastatic lymph nodes were 5 mm or less in diameter \[[@R52]\]. The lack of correlation between lymph node size and metastatic infiltration has been reported in studies of other solid tumors \[[@R53]-[@R57]\]. Therefore, differentiating between benign and metastatic lymph nodes may be unreliable when lymph node size is used as a criterion \[[@R52]\]. Lymph node metastasis of EGC is still predicted by means of the presence or absence of certain tumor characteristics postoperatively \[[@R19], [@R43], [@R58]\].

It is very difficult for conventional transabdominal US to visualize the gastric cancer without any assistant because of the interference of gas in the stomach (Figures [1 A](#F1){ref-type="fig"}, [2 A](#F2){ref-type="fig"}). Although the likelihood of detecting gastric cancer followed by oral contrast agent exist (Figures [1 B](#F1){ref-type="fig"}, [2 B](#F2){ref-type="fig"}), the sensitivity of diagnosis of LNM of EGC by oral contrast-enhanced ultrasonography is still very low (Figure [1 B](#F1){ref-type="fig"}), with a rate of 33.3% in our study.

Double contrast-enhanced ultrasonography could be considered as a valid method to evaluate the microcirculatory perfusion of gastric cancer using intravenous contrast agents, based on taking an oral ultrasonic agent. An oral ultrasonic agent which was composed by a kind of soya derivative has some contribution for this study, such as the how to evacuate the air in stomach and distend the gastric lumen for displaying the lesions prominently. After taking the oral contrast agent, the stomach lumen appeared as an iso-echoic homogenous acoustic window, and its effect was superior to water because the evacuation was slow. SonoVue, a microbubble contrast material with a mean diameter of 2.5 µm, is a blood pool agent that does not cross into the interstitial space \[[@R59], [@R60]\].

Because such microbubbles flow with red blood cells, the injected microbubbles act as markers for tissues that are densely populated with vessels, thereby, suggesting that angiogenesis is the foundation for tumor enhancement \[[@R61], [@R62]\]. Angiogenesis is important for tumor growth and metastasis \[[@R63]-[@R65]\]. Angiogenesis is an unfavorable factor related to LNM in EG \[[@R66]\]. Double contrast-enhanced ultrasonography can be used to assess vascularity and the biological behavior of gastric carcinomas *in vivo* \[[@R67]\].

Because of this finding, we sought to predict the LNM in EGC preoperatively using DCUS by means of certain primary tumor characteristics. Although the specificity decreased from 98.4% with oral contrast-enhanced ultrasonography to 60.7% with DCUS (*p* \< 0.005), the sensitivity was improved from 33.3% with oral contrast-enhanced ultrasonography to 86.7% with DCUS (*p* \< 0.005). Because the presence of LNM has a strong adverse influence on the prognosis of patients with EGC \[[@R11], [@R22], [@R68]-[@R70]\], the high sensitivity of diagnosis is more important. The agreement of this diagnosis is very good (κ value = 0.89).

Intratumor microvessel density (MVD) is a reliable index of tumor angiogenesis \[[@R71]\]. Many previous studies of gastric carcinoma have demonstrated that angiogenesis is one of the crucial factors for tumor development and progression in gastric cancer \[[@R72], [@R73]\]. Angiogenesis is closely correlated with biological behaviors, degree of differentiation, and metastatic lymphadenopathy in gastric cancer \[[@R74]\]. Contrast-enhanced intensity has a strong positive linear correlation with MVD in gastric carcinoma \[[@R67]\]. Therefore, contrast-enhanced intensity is a promising index to evaluate the growth and progression of gastric carcinoma. This study demonstrates that depth of tumor size and degree of differentiation both relate to contrast-enhanced intensity (*p* \< 0.05), which indicates that contrast-enhanced intensity can be used to assess the biological behavior of EGC *in vivo*. We found that degree of differentiation was significantly associated with LNM (*p* \< 0.05), similar to that indicated by other authors \[[@R18], [@R19], [@R75]\].

Although contrast enhanced ultrasonography can assess whether LNM is present in the patients with DCUS, the location and number of lymph nodes cannot be determined. Further studies are required to evaluate LNM with precise quantitative analysis.

In conclusion, DCUS shows promise as a new noninvasive, convenient, and repeatable method to evaluate LNM in EGC and the prognosis of EGC preoperatively. Identification of EGC with marked hyperenhancement allows closer postoperative follow-up and possibly the use of drugs targeted for the growth of new vessels to prevent recurrence.
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![A case of EGC with LNM confirmed pathologically after operation. **A:** The early gastric cancer and LNM can not be detected with conventional transabdominal US. **B:** The early gastric cancer (white arrow) can be clearly demonstrated in the oral contrast-enhanced ultrasonography image, but LNM can not be demonstrated. **C:** Compared with the adjacent normal gastric wall (white arrow), marked hyperenhancement of the EGC (T) in DCUS image was shown during the early arterial phase\
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![A case of EGC without LNM confirmed pathologically after operation. **A:** The early gastric cancer and LNM could not be detected with conventional transabdominal US. **B:** The early gastric cancer (white arrow) and LNM (green arrow) can be clearly demonstrated in the oral contrast-enhanced ultrasonography image. **C:** Compared with the adjacent normal gastric wall (white arrow), unmarked hyperenhancement of the EGC (green arrow) in DCUS image was shown during the early arterialphase\
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###### 

The sensitivity, specificity, and Youden\'s index of oral contrast-enhanced ultrasonography (CEUS) and double contrast-enhanced ultra - sonography (DCUS) in detecting lymph node metastasis

                  Sensitivity \[%\]   Specificity \[%\]   Youden\'s index
  --------------- ------------------- ------------------- -----------------
  **Oral CEUS**   33.3                98.4                0.317
  **DCUS**        86.7                60.7                0.474

###### 

The relationship between different clinicopathological characteristics and the rate of lymph node metastasis as well as the contrast-enhanced intensity

  Factors                  Node negative   Node positive   Value of *p*   Marked hyperenhancement   Unmarked hyperenhancement   Value of p
  ------------------------ --------------- --------------- -------------- ------------------------- --------------------------- ------------
  Age \[years\]            61.0 ±13.5      57.7 ±10.3      0.382          58.5 ±10.9                58.2 ±11.1                  0.887
  Male                     9               39              0.777          21                        27                          0.260
  Female                   6               22              16             12                                                    
  Upper                    2               2               0.291          2                         2                           0.446
  Middle                   2               8               3              7                                                     
  Lower                    11              51              32             30                                                    
  Tumor diameter \[mm\]    31.4 ±9.6       30.8 ±12.0      0.866          35.4 ±13.1                26.8 ±7.80                  0.001
  Mucosa                   4               32              0.073          14                        22                          0.105
  Submucosa                11              29              23             17                                                    
  **Histological type:**                                                                                                        
  Differentiated           5               39              0.032          16                        28                          0.012
  Undifferentiated         10              22              21             11                                                    
